Completed PHASE4 INTERVENTIONAL 2-arm NCT00795717

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial (HALO)

Sponsor: Tufts University

Conditions Cardiovascular Disease HIV Infection

Updated 8 times since 2017 Last updated: Aug 30, 2019 Started: Jul 31, 2008 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cardiovascular Disease and HIV Infection and is currently completed. Tufts University leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Oct 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Oct 2019 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tufts University

Data source: Tufts University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States